Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South thames trial of antibiotics in myocardial infarction and unstable angina (STAMINA)

Circulation

Volumn 106, Issue 10, 2002, Pages 1219-1223

  Stone, Adam F M ^a   Mendall, Michael A ^a   Kaski, Juan Carlos ^a   Edger, Tracey M ^a   Risley, Paul ^a   Poloniecki, Jan ^a   Camm, A John ^a   Northfield, Timothy C ^a  

^a MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Coronary disease; Infection; Inflammation

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; C REACTIVE PROTEIN; FIBRINOGEN; METRONIDAZOLE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

ACUTE DISEASE; ACUTE HEART INFARCTION; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ATHEROSCLEROSIS; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANGINA, UNSTABLE; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; AZITHROMYCIN; BIOLOGICAL MARKERS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SYNDROME;

EID: 0037015254     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000027820.66786.CF     Document Type: Article

References (33)

1. Atherosclerosis: An inflammatory disease
2. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis
3. C Reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study
4. Dental infection and the risk of new coronary events: Prospective-study of patients with documented coronary artery disease
5. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors
6. Helicobacter pylori infection and coronary heart disease in middle-aged men: Prospective relations in a nested case-control study
7. Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis
8. Unstable angina: A classification
9. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study
10. Evaluation of PCR, culture, and serology for diagnosis of Chlamydia pneumoniae respiratory infections
11. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction
12. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Primary clinical results of the ACADEMIC study
13. Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction
14. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease
15. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection With Chlamydia (ACADEMIC) study
16. Effect of 3 months antimicrobial treatment with Clarithromycin in acute non-Q-wave coronary syndrome
17. In vitro and in vivo activities of azithromycin, a new macrolide antibiotic, against Chlamydia
18. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children
19. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment
20. Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae in lung tissue in experimental pneumonitis
21. Problems and perspectives in the treatment of respiratory infections caused by atypicals
22. Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori
23. Comparison of macrolides
24. Erythromycin suppresses interleukin 6 expression by human bronchial cells: A potential mechanism of its anti-inflammatory action
25. Non-antibiotic effects of antibiotics
26. In-vitro drug susceptibility of Chlamydia sp TWAR
27. Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection: Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients
28. Antibiotics and inflammatory bowel diseases
29. Effects of metronidazole and its metabolites on histamine immunosuppression activity
30. Modulation of lymphocyte adrenergic receptors and transformation responses by therapeutic drugs
31. Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells
32. In vivo effect of omeprazole on HLA-DR expression and the monocyte-macrophage function in patients with duodenal ulcer disease
33. Impact of infectious burden on extent and long-term prognosis of atherosclerosis